Two cases of primary CNS lymphoma treated with rituximab and temozolomide
원발성 중추신경계 림프종에서 리툭시맵과 테모졸로미드 병합치료
이, 윤석; 김, 무정; 이, 현우; 박, 준성; 조, 경기; 김, 효철
The Korean journal of medicine, 75(suppl.3):S806-S810, 2008
The Korean journal of medicine; 대한내과학회지
저자들은 두통, 기억력 감퇴, 시야결손의 증상을 주소로 내원한 환자에서 두경부 MRI를 시행하여 원발성 중추신경계 림프종을 의심하였고, 뇌정위적 생검을 시행하여 확진한 후 rituximab과 temozolomide로 병합치료 후 특이 부작용 없이 완전관해에 도달하였기에 문헌고찰과 함께 보고하는 바이다.
Primary CNS lymphoma (PCNSL) is rare, occurring in 2～3% of all non-Hodgkin’s lymphoma. However, in recent years the incidence has increased. To date, the main treatment modalities are radiation therapy, steroids, methotrexate, or combination therapies. The response and overall prognosis remain poor. Use of CHOP in PCNSL has been disappointing in overall response, presumably due to poor penetration through the blood-brain barrier (BBB). We experienced excellent results using a combination of rituximab and the BBB-penetrating alkylating agent temozolomide. Two cases were diagnosed with PCNSL (diffuse large B cell lymphoma) with strong CD 20 positivity. They were placed on a 3-week cycle of rituximab 375 mg/m2 and 5 days of temozolomide 150 mg/m2. After six cycles of chemotherapy, repeat MRIs showed complete remission. Overall, tolerance to chemotherapy was excellent, with no significant marrow suppression. The combination of rituximab and temozolomide may be an effective regimen for the treatment of primary CNS lymphoma.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :3,104,439
Total Download :1,270,125
Today View :864
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.